戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              u-PA is 47-fold more active than t-PA for cleavage of a
2 ino terminal fragment of u-PA inhibited 125I-u-PA binding to platelets with a mean IC50 of 65 and 58
3       In contrast to resting platelets, 125I-u-PA did not bind to thrombin-induced platelets.
4 membrane and of U937 cell proteins with 125I-u-PA revealed a u-PA binding protein of approximately 70
5                                            A u-PA complex was further shown by enzyme-linked immunoso
6 U937 cell proteins with 125I-u-PA revealed a u-PA binding protein of approximately 70 kD in the plate
7 by receptor-bound urinary-type Pg activator (u-PA) and initiated a Ca(++) signaling cascade.
8 ent of urokinase-type plasminogen activator (u-PA) and PAI-1.
9 -PAR) binds urokinase plasminogen activator (u-PA) and participates in plasminogen activation in addi
10  activators urokinase plasminogen activator (u-PA) and tissue plasminogen activator (t-PA).
11 ation, urokinase-type plasminogen activator (u-PA) and u-PA receptor were observed in the immunopreci
12 genous urokinase-type plasminogen activator (u-PA) has been identified in platelet membrane, and plat
13 ity of urokinase-type plasminogen activator (u-PA) increases very rapidly (within 1 minute) after par
14  Human urokinase type plasminogen activator (u-PA) is a member of the chymotrypsin family of serine p
15 e that urokinase-type plasminogen activator (u-PA) is importantly involved in fibrinolysis, but its p
16 r (t-PA) or urokinase plasminogen activator (u-PA) levels, which remained unchanged.
17  binds urokinase-type plasminogen activator (u-PA) through specific interactions with uPAR domain 1,
18 LN endogenous urinary plasminogen activator (u-PA), as well as by added tissue Pg Activator (t-PA), s
19 A) and urokinase-type plasminogen activator (u-PA), by modifying the technique of substrate phage dis
20 PA) or urokinase-type plasminogen activator (u-PA).
21 otease urokinase-type plasminogen activator (u-PA).
22 gen (Plg) by either urokinase Plg activator (u-PA) or tissue Plg activator (t-PA).
23 ively, our data show that in culture, active u-PA is present and cleaves scHGF to tcHGF in the contex
24  membrane contains a specific, high affinity u-PA-binding protein that is distinct from u-PAR.
25 s using either a polyclonal antibody against u-PA or, since u-PA functions in the context of its rece
26                                Both t-PA and u-PA hydrolyze the engineered proteins at the inserted t
27             Cleavage of proteins by t-PA and u-PA is sequence selective.
28 ibitor, antibodies directed against t-PA and u-PA, and epsilon-aminocaproic acid, a lysine analog tha
29 f the protease domains of two-chain t-PA and u-PA, and molecular modeling of the corresponding single
30 ary physiological inhibitor of both t-PA and u-PA, confirmed this prediction and indicated a predomin
31 nhibitor-1 (PAI-1), an inhibitor of t-PA and u-PA, in a rat model of aortic aneurysm.
32 kinase-type plasminogen activators (t-PA and u-PA, respectively), of their specific inhibitor (PAI-1)
33 a substrate to discriminate between t-PA and u-PA.
34 kinase-type plasminogen activator (u-PA) and u-PA receptor were observed in the immunoprecipitates of
35 the lungs of bleomycin-treated Pg(-)(/-) and u-PA(-)(/-) mice.
36 ts, we used inactive variants of trypsin and u-PA whose catalytic serine S195 had been replaced by al
37 lasminogen activation by platelet-associated u-PA was studied.
38  t-PA for cleavage of a sequence known to be u-PA selective within small peptide substrates, whereas
39                                      Because u-PA, t-PA, and plasmin have a limited proteolytic activ
40 or was similar to wild-type u-PAR in binding u-PA and initiating plasminogen activation.
41  the primary physiological inhibitor of both u-PA and t-PA, that inhibited u-PA approximately 70 time
42   To test whether the active, receptor-bound u-PA from the cell cultures was cleaving scHGF, iodinate
43 logical significance of receptor cleavage by u-PA, we engineered and expressed a two-chain urokinase
44 ved as much as 120 times more efficiently by u-PA than by tissue type plasminogen activator (t-PA), a
45 e cleaved 840-5300 times more efficiently by u-PA than peptides containing the physiological target s
46 investigated using recombinant, single chain u-PA.
47 r for u-PA and a portion of the single-chain u-PA (scu-PA) intrinsic to blood is tightly associated w
48 ves scu-PA to the mature protease, two-chain u-PA (tcu-PA), which is efficiently and irreversibly inh
49              These findings may help explain u-PA-mediated physiological fibrinolysis and have implic
50  a value of 9 for wild type t-PA and 250 for u-PA.
51 te PA activity in parallel with the mRNA for u-PA.
52 echanism, as they carry a novel receptor for u-PA and a portion of the single-chain u-PA (scu-PA) int
53 dine 144 of t-PA to an acidic residue, as in u-PA, selectively suppressed the activity of single-chai
54 se in PAI-1 and TF mRNAs and the decrease in u-PA mRNA in the kidneys of MRL lpr/lpr mice suggests th
55 nhibitor-1 RNA and protein and a decrease in u-PA RNA as noted by quantitative reverse transcriptase-
56 tion to these changes in PAI-1, decreases in u-PA mRNA and increases in TF mRNA were demonstrated in
57                                    Levels in u-PA(-)(/-) and u-PAR(-)(/-) mice were similar to those
58 ibitor of both u-PA and t-PA, that inhibited u-PA approximately 70 times more rapidly than it inhibit
59 stantially more PAI-1 and substantially less u-PA were present in the atherectomy samples from subjec
60 t membrane degradation through cell-mediated u-PA activation of Pg with possible involvement of matri
61                  A mutant recombinant murine u-PA that retains receptor binding but not proteolytic a
62 ors cells secrete an inhibitor of the murine u-PA receptor.
63                                       Mutant u-PA and a reporter gene pRK luciferase were transfected
64             Several clones expressing mutant u-PA and luciferase were identified by Western blotting,
65 tional MAT-LyLu cell lines expressing mutant u-PA.
66 itory activity of PAI-1 against t-PA but not u-PA suggested that the mechanism of loop insertion is s
67  report, the mechanism of the association of u-PA with platelets was investigated using recombinant,
68                                Complexion of u-PA with a platelet membrane protein was also shown by
69 eled u-PA and the amino terminal fragment of u-PA inhibited 125I-u-PA binding to platelets with a mea
70 ighly selective, high affinity inhibitors of u-PA and, consequently, may facilitate the development o
71 also shown by gel filtration of a mixture of u-PA and platelet membrane proteins.
72          It also suggests that modulation of u-PA activity by various growth factors is relevant for
73                              Reactivation of u-PA was not due to the direct action of thrombin, but r
74 e-dependent (1 to 10 u/mL) partial return of u-PA activity.
75  this study to determine whether the role of u-PA in prostate cancer induced angiogenesis and seconda
76      In view of the well-recognized roles of u-PA as one of the major initiators of the matrix proteo
77  optimal subsite occupancy for substrates of u-PA.
78 were labile to selective cleavage by t-PA or u-PA when in the context of a peptide were introduced in
79 o the cell in the presence of either t-PA or u-PA, conversion to Lys-Pg was observed, but conversion
80 enhanced interstitial fibrosis in Pg(-)(/-), u-PA(-)(/-), and t-PA(-)(/-) mice relative to WT and u-P
81 omycin-treated WT mice and not in Pg(-)(/-), u-PA(-)(/-), and u-PAR(-)(/-) mice or saline controls.
82 ect is pronounced for the selective protease u-PA.
83 n platelets were incubated with radiolabeled u-PA, the u-PA was found to specifically and saturably b
84 a polyclonal antibody against u-PA or, since u-PA functions in the context of its receptor (u-PAR), a
85     These findings suggest that cell surface u-PA contributes to prostate cancer growth by enhancing
86 version to tc-u-PA and incorporation into tc-u-PA.PAI complexes) in an LRP/alpha2MR-dependent manner,
87 hoblasts by facilitating the clearance of tc-u-PA.PAI complexes and regeneration of unoccupied cell s
88 UK (primarily following its conversion to tc-u-PA and incorporation into tc-u-PA.PAI complexes) in an
89 nd complexes between two-chain urokinase (tc-u-PA) and plasminogen activator inhibitor type-1 (PAI-1)
90 e upon binding to its cellular cofactor, the u-PA receptor (u-PAR), hence activating an enzymatic cas
91 al or a polyclonal antibody specific for the u-PA cell-surface receptor (u- PAR), failed to show evid
92 s were incubated with radiolabeled u-PA, the u-PA was found to specifically and saturably bind to the
93 ent, the majority was of the urokinase type (u-PA) as determined by neutralization studies using eith
94                                    Unlabeled u-PA and the amino terminal fragment of u-PA inhibited 1
95 f t-PA, however, is not shared by urokinase (u-PA), a plasminogen activator that is very closely rela
96 plasminogen activators (including urokinase (u-PA), streptokinase (SK), and tissue plasminogen activa
97 e plasminogen activator (t-PA) or urokinase (u-PA) resulted in rapid decreases of fluorescence coinci
98 her tissue Pg activator (t-PA) or urokinase (u-PA) were compared when these Pg forms were either boun
99 ient for plasminogen (Pg(-)(/-)), urokinase (u-PA(-)(/-)), urokinase receptor (u-PAR(-)(/-)), or tiss
100    Binding of the serine protease urokinase (u-PA) to its receptor on tumor cell surfaces facilitates
101 n to take up exogenous high molecular weight u-PA from the ambient medium.
102           Similar results were obtained when u-PA was used as activator.
103 oportionate elevation of PAI-1 compared with u-PA observed in atheromatous material extracted from ve

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top